StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a research note released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Cara Therapeutics Price Performance
NASDAQ CARA opened at $0.27 on Friday. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.40. The company has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.45. The firm has a market capitalization of $14.54 million, a P/E ratio of -0.12 and a beta of 0.70.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. As a group, equities research analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current year.
Institutional Inflows and Outflows
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Recommended Stories
- Five stocks we like better than Cara Therapeutics
- How to Choose Top Rated Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Find Undervalued Stocks
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.